OpenEvidence is Nadler's second act. 1M physician questions a day.
Daniel Nadler founded Kensho in 2013 and sold it to S&P Global for $700M in 2018 — at the time, one of the larger AI-platform acquisitions in financial-services data infrastructure. His second act is OpenEvidence, a free, physician-only AI search platform grounded in NEJM, JAMA, NCCN guidelines, and other institutional clinical-evidence sources. By mid-2026 the platform was handling 1M+ physician questions per day, with 40% of U.S. physicians using it daily and 750K physicians worldwide on the platform.
The funding arc compressed accordingly. February 2025: $75M Series A. July 2025: $210M Series B. October 2025: $200M Series C at a $6B valuation. January 2026: $250M Series D at a $12B valuation. By venture-class standards, $75M to $12B inside twelve months is an extraordinary compression. The compression is not just about the growth metrics. The compression is about venture-class conviction that OpenEvidence has captured a category that did not previously exist at scale. Physician-facing AI search was a fragmented category pre-OpenEvidence. By Q1 2026 it is a category with a $12B-valued category leader and a clear adoption mechanism. The funding arc is the venture-class reading of the category-creation event.
The argument that holds is that the arc is instructive about what works in physician-facing AI deployment, and the instructive elements run through three plays Nadler executed cleanly.
The first is institutional-anchor licensing as the credibility mechanism. OpenEvidence is grounded in NEJM, JAMA, and NCCN content. The licensing arrangements are costly to negotiate and structurally hard to replicate, and they produce a credibility floor that no general-frontier-model AI search can match for physician audiences. Physicians trust the source citations because the sources are the ones their training and continuing-education calibrated them to trust. The anchor strategy is, in operating practice, the same one Nadler ran at Kensho with S&P-data licensing: the anchor is the moat, the AI capability is the surface-layer expression. Operators in adjacent healthtech-AI categories who want to model the playbook should be designing their credibility mechanisms around equivalent institutional anchors, not around AI capability differentiation.
The second is free-to-physician adoption as the distribution mechanism. OpenEvidence is free for physicians, which produces zero-friction adoption that paid-tier products cannot match in the physician demographic. Physicians don't have procurement authority for individual-license SaaS; they have research-and-recommendation authority for tools the institution might later procure. By making the tool free at the individual level, OpenEvidence captures direct adoption that the institution-level procurement cycle cannot bottleneck. The 40%-daily-use rate is the structural proof that the mechanism works. The operator-class question for adjacent categories is whether the equivalent free-to-end-user distribution can be supported by the unit economics — which depend on the data flywheel, the institutional partnerships, or the eventual paid-tier conversion path.
The third is venture-class compression as a category-creation event in its own right. The compressed funding arc isn't merely a consequence of growth; it is itself a market-making artifact. By committing $12B of valuation in twelve months, the venture class signals that OpenEvidence has become the default platform-layer for physician-facing AI tools. The signal forces other operators in the category to position relative to OpenEvidence, which compounds OpenEvidence's category-leader gravity. _The valuation is the platform commitment, not just the price._
The thing that crosses pillars is that the institutional-anchor-plus-free-distribution playbook recurs across categories where credibility is the binding adoption constraint. Legal-AI has an analog: institutional-anchor licensing for case-law-grounded research, free-to-attorney distribution where the unit economics work. Finance-AI has an analog: anchor-data licensing, free-to-advisor distribution in some sub-segments. Each adjacent category has its own version of the OpenEvidence arc, with category-specific calibration. The playbook does not generalize trivially — in healthtech-AI categories where the credibility mechanism is harder to assemble (clinical-decision-support categories that require regulatory-class validation, prevention categories that require longitudinal-outcome evidence), the free-to-end-user distribution does not work the same way. Most copies of the OpenEvidence playbook fail because most categories don't meet the credibility-mechanism conditions.
What survives the copy-failure rate is the operator-tier profile that Nadler represents. Serial-founder healthtech operators with platform-class venture experience bring fundraising fluency, anchor-licensing-strategy experience, and a category-creation playbook from the prior platform. The combination produces the kind of execution velocity that first-time-founder healthtech operators struggle to match. Investors looking for category-creation bets in healthtech-AI should be tracking the serial-founder profile explicitly — the operating-execution-class differential is durable.
The $12B valuation is, in operating terms, the venture-class commitment to OpenEvidence becoming the platform-infrastructure layer for physician-facing AI tools. If the company stays a single-product physician-AI-search tool, the valuation is over-priced. If it executes on platform-layer expansion — becoming what Stripe is for payments or Twilio is for communications, in the physician-facing AI category — the valuation is operating-coherent.
The read that survives is that OpenEvidence is the canonical 2024-2026 healthtech-AI category-creation case study, the playbook is structurally specific to the credibility-and-distribution conditions Nadler navigated, and the operator lesson is to study the playbook with operating-class precision rather than to default to "we are the OpenEvidence of [adjacent category]" pitch language without engaging with the conditions that made the playbook work.
OpenEvidence is Nadler's second act. 1M physician questions a day is the structural proof that the playbook works. The $12B valuation is the venture-class commitment to the platform-class expansion. Operators who study the playbook to its conditions are positioned to capture similar category-creation events in adjacent categories. Operators who copy the surface elements without the conditions are not.
—TJ